Latest News for GBS
Hansa Biopharma reports positive efficacy and safety results from Idefirix European post authorization study in kidney transplantation
Hansa Biopharma Announces Late-Breaking Abstract from ConfIdeS Phase 3 Trial Selected for Oral Presentation at ATC 2026 PR News
Filing date: May 20, 2026GAAP diluted EPS was $11.09, which is higher than the estimated EPS of $10.65.Revenue was $8,558 million, which is below the estimated
Hansa Biopharma enters into â¬115 million licensing agreement with SERB Pharmaceuticals for IDEFIRIX in Europe and MENA PR New
CONSHOHOCKEN, Pa., May 11, 2026 (GLOBE NEWSWIRE) -- May is GBS|CIDP Awareness Month and this year marks 110 years since the discovery of Guillain-Barré syndrome (GBS), which was first identified and named in 1916 by French neurologists Georges Guillain, Jean Alexandre Barré, and André Strohl.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for GBS.
U.S. House Trading
No House trades found for GBS.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.